Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-03-26 | Ms. Wendell is Senior Advisor at Perella Weinberg Partners L.P. ... Committees: Quality, Compliance and Technology. ... Ms. Wendell joined the Board in February 2019. No compensation shown in 2018 Director Compensation Table. |
| 2020-03-17 | Ms. Wendell served as Senior Vice President of Strategy and Business Development at Covidien. ... Committees: Quality, Compliance and Technology. ... Director Compensation Table shows total compensation of $322,547. |
| 2021-03-22 | Ms. Wendell served as Senior Vice President of Strategy and Business Development at Covidien ... Committees: Quality, Compliance and Technology. 2020 compensation: $323,445. |
| 2022-03-21 | Ms. Wendell served as Senior Advisor at Perella Weinberg Partners L.P. Committees: Compensation and Quality, Compliance and Technology. |
| 2023-03-23 | Extensive expertise in the healthcare sector in the areas of global business development and licensing. |
| 2024-03-25 | Ms. Wendell served as Senior Advisor at Perella Weinberg Partners L.P. ... Committees: Compensation and Human Capital and Quality and Regulatory Compliance ... Director Compensation Table shows total compensation of $352,977. |
| 2025-03-25 | Amy A. Wendell Independent Director Age 64 Director since 2019 Committees: Compensation and Human Capital, Quality and Regulatory Compliance and Operating Biography Ms. Wendell served as Senior Advisor at Perella Weinberg Partners L.P., a global financial services firm, from January 2016 to May 2019 where she consulted on strategy, corporate finance and investing practices in the healthcare industry. From 2015 to September 2018, Ms. Wendell served as a Senior Advisor at McKinsey & Company (McKinsey), a management consulting firm, in its strategy and corporate finance practice and also served as a member of McKinsey’s Transactions Advisory Board. She previously served as Senior Vice President of Strategy and Business Development and Licensing at Covidien plc (Covidien) from 2006 to 2015, where she led the company’s strategy and portfolio management initiatives and managed business development activities. From 1986 to 2015, Ms. Wendell held roles of increasing responsibility at Covidien (including its predecessors, Tyco International plc and Kendall Healthcare Products Company), from engineering to product management and business development. Ms. Wendell currently serves as a director of Axogen, Inc., Hologic, Inc. and Solventum Corporation. Ms. Wendell previously served as a director of Por Cristo, a non-profit charitable medical service organization involved in healthcare work for at-risk women and children in Latin America. Key Attributes, Experience and Skills Extensive expertise in the healthcare sector in the areas of global business development and licensing, portfolio management, mergers and acquisitions, resource allocation and identifying new market opportunities, as well as significant restructuring and integration experience, including as a result of her roles at Covidien and its predecessors. |
Data sourced from SEC filings. Last updated: 2025-07-01